Highly stable, ligand-clustered “patchy” micelle nanocarriers for systemic tumor targeting
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A novel linear-dendritic block copolymer has been synthesized and evaluated for targeted delivery. The use of the dendron as the micellar exterior block in this architecture allows the presentation of a relatively small quantity of ligands in clusters for enhanced targeting, thus maintaining a long circulation time of these “patchy” micelles. The polypeptide linear hydrophobic block drives formation of micelles that carry core-loaded drugs, and their unique design gives them an extremely high level of stability in vivo. We have found that these systems lead to extended time periods of increased accumulation in the tumor (up to 5 days) compared to non-targeted vehicles. We also demonstrate a 4x increase in efficacy of paclitaxel when delivered in the targeted nanoparticle systems, while significantly decreasing in vivo toxicity of the chemotherapy treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924 · cited 1×
“We prepared paclitaxel PTX(22,23) encapsulated LDP “patchy” micelles that present folate in clusters and investigated the efficacy of the optimized patchy micellar system in tumor targeting, its viability as a stable drug carrier in serum and in vivo, as well as its efficacy for intravenous delivery of chemotherapeuti…”
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821 · cited 1×
“While clinical trials of micellar delivery systems have demonstrated improved pharmacokinetics and a greater tolerance with patients, dose-limiting toxicities attributed to the drug still occurs at higher dosage levels(9-11), suggesting that on some level, the encapsulated drug dissociates from the carrier in vivo.”
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734 · cited 1×
“For example, Genexol, a poly(ethylene glycol)-block-poly(D,L-lactide) linear polymer carrying PTX was found to have half-lives of less than 1 h(35).”
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541 · cited 1×
“While clinical trials of micellar delivery systems have demonstrated improved pharmacokinetics and a greater tolerance with patients, dose-limiting toxicities attributed to the drug still occurs at higher dosage levels(9-11), suggesting that on some level, the encapsulated drug dissociates from the carrier in vivo.”
Chen, H., Kim, S., He, W., Wang, H., Low, P. S., Park, K., & Cheng, J.-X. (2008) · Langmuir · doi:10.1021/la703570m · Cited by 311
Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603855 · Cited by 290 · cited 1×
“While clinical trials of micellar delivery systems have demonstrated improved pharmacokinetics and a greater tolerance with patients, dose-limiting toxicities attributed to the drug still occurs at higher dosage levels(9-11), suggesting that on some level, the encapsulated drug dissociates from the carrier in vivo.”
Cited by
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
The effects of polymeric nanostructure shape on drug delivery
Venkataraman, S., Hedrick, J. L., Ong, Z. Y., Yang, C., Ee, P. L. R., Hammond, P. T., & Yang, Y. Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.016 · Cited by 510
Self-citationNonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration
Zhou, Z., Liu, X., Zhu, D., Wang, Y., Zhang, Z., Zhou, X., Qiu, N., Chen, X., & Shen, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.021 · Cited by 379
Sahlgren, C., Meinander, A., Zhang, H., Cheng, F., Preis, M., Xu, C., Salminen, T. A., Toivola, D., Abankwa, D., Rosling, A., et al. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700258 · Cited by 315
Self-Assembled Tat Nanofibers as Effective Drug Carrier and Transporter
Zhang, P., Cheetham, A. G., Lin, Y.-A., & Cui, H. (2013) · ACS Nano · doi:10.1021/nn401667z · Cited by 209
Miyazawa, T., Itaya, M., Burdeos, G. C., Nakagawa, K., & Miyazawa, T. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s298606 · Cited by 185
“Poom et al prepared PEG nanomicelles containing anticancer drug (paclitaxel) and reported that the accumulation of paclitaxel in rat tumor tissue decreased to 1% ID/g of tissue after 3 days when the PEG nanomicelles were administered (passive targeting only), whereas the drug accumulation of more than 5% ID/g of tissu…”
BackgroundDawidczyk, C. M., Russell, L. M., & Searson, P. C. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00069 · Cited by 164
“…Medina et al., 2011; Zhang et al., 2011b; Fonge et al., 2012; Helbok et al., 2012) (Rossin et al., 2005; Khemtong et al., 2009; Zhan et al., 2010; Poon et al., 2011; Zhang et al., 2011a; Xiao et al., 2012), iron oxide (Natarajan et al., 2008; Kumar et al., 2010; Yang et al., 2011), graphene…”
BackgroundBranched and Dendritic Polymer Architectures: Functional Nanomaterials for Therapeutic Delivery
Cook, A. B., & Perrier, S. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201901001 · Cited by 159
Ke, X., Ng, V. W. L., Ono, R. J., Chan, J. M. W., Krishnamurthy, S., Wang, Y., Hedrick, J. L., & Yang, Y. Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.061 · Cited by 146
PEGylated nanomedicines: recent progress and remaining concerns
Vllasaliu, D., Fowler, R., & Stolnik, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866651 · Cited by 137
“Elegant formulation techniques and chemistries have been used to fabricate nanocarriers displaying controlled arrangement of one or more targeting moieties on their surface, with literature examples ranging from ‘patchy’ folate ligand-clustered micelles [83-85] to nanocarriers with variable surface densities of mannos…”
BackgroundWu, W., Zhang, C., Lin, W., Chen, Q., Guo, X., Qian, Y., & Zhang, L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119575 · Cited by 47
Metadata
- Authors
- Poon, Z., Lee, J. A., Huang, S., Prevost, R. J., & Hammond, P. T.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 7
- Issue
- 2
- Pages
- 201-209
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W2142098453
- Cited by
- 66
- References
- 7
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.